Samsara Vision, a company dedicated to restoring vision and independence to patients living with late-stage, age-related macular degeneration (AMD) through advanced visual prosthetic devices, today announced the expansion of its ongoing Concerto clinical study evaluating the investigational Smaller-Incision New-Generation Implantable…
hape Memory Medical Inc., developer of the only commercially available volume-expanding shape memory polymer for endovascular embolization, has announced that it has reached 50% enrollment in its ongoing AAA-SHAPE Pivotal Trial. This milestone marks the successful treatment of the 90th…
Delix Therapeutics, a clinical-stage neuroscience company advancing a new generation of non-hallucinogenic neuroplastogens for the treatment of serious neuropsychiatric and neurodegenerative disorders, has announced the publication of a peer-reviewed study in ACS Chemical Neuroscience. The paper, titled “Zalsupindole is a…
Arcitecta, a pioneer in innovative data management software, recently joined leading research institutions and technology partners—including Spectra Logic, Wasabi, Cerabyte, and IQM—at the inaugural DATAKAMER 2025 event. Hosted by the Dana-Farber Cancer Institute in Boston, Massachusetts, this exclusive, one-day forum…
At the American Society of Human Genetics (ASHG) 2025 industry session, Oxford Nanopore Technologies announced a series of major updates aimed at advancing translational and clinical human genetics. The company’s new developments are designed to help researchers and clinicians achieve…
ClearB Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing therapies aimed at achieving functional cure in patients with chronic hepatitis B (CHB) infection, announced that the sentinel subject safety review in their ongoing Phase 1b study of CLB-4000 supports…
PeptiDream Inc., PDRadiopharma Inc. — a wholly owned subsidiary of PeptiDream — and Curium Group, a global leader in nuclear medicine, have announced the initiation of a registrational Phase 2 clinical trial in Japan for 64Cu-PSMA-I&T, a novel PET radiopharmaceutical…
Eradivir Inc., a clinical-stage biotechnology company leveraging the immune system to treat infectious diseases, today announced the successful completion of its Phase 2a clinical trial evaluating EV25, a novel therapy for influenza. The trial demonstrated that EV25 is safe, well-tolerated,…
Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on integrating advanced engineering with cutting-edge laboratory and in silico research to accelerate drug discovery, today announced that new data from its ongoing Phase 2 study of EIK1001 (TeLuRide-005) will be…
Augurex Life Sciences Corp., a leading innovator in autoimmune-based diagnostics, today announced a strategic agreement with MitogenDx, a Canadian specialty laboratory focused on autoimmune and rheumatology diagnostic testing. Under the terms of the agreement, MitogenDx will offer the JOINTstat® blood…